- Open Access
Vitamin D and VDR gene polymorphism (FokI) in epithelial ovarian cancer in Indian population
© Mohapatra et al.; licensee BioMed Central Ltd. 2013
- Received: 2 April 2013
- Accepted: 22 May 2013
- Published: 26 May 2013
Vitamin D deficiency and vitamin D receptor (VDR) gene polymorphism, FokI, is reported to increase the risk of many cancers. Role of vitamin D and its receptor polymorphisms in ovarian cancer has not been clearly defined.
To study the levels of serum vitamin D and occurrence of vitamin D receptor gene polymorphism (FokI) in cases of ovarian cancer.
Material and methods
FokI genotyping was done by PCR-RFLP technique and vitamin D levels were estimated by chemiluminescence immunoassay.
Serum vitamin D levels were significantly (p < 0.03) lower in ovarian cancer cases as compared to controls. The homozygous (TT) and heterozygous (CT) genotype predispose to the development of ovarian cancer in Indian population (OR: 2.37, 95% CI: 1.04-5.44) as compared to the homozygous (CC) genotype. Vitamin D deficiency and VDR gene polymorphism (FokI) act non-synergistically (p value < 0.4).
Low blood levels of vitamin D and VDR receptor polymorphism (FokI) might be a risk factor for the development of ovarian cancer. Other novel ligands of vitamin D receptor might be responsible for the non-synergistic effect.
- Ovarian Cancer
- Epithelial Ovarian Cancer
- Ovarian Cancer Patient
- Serum Vitamin
- Ovarian Cancer Risk
Ovarian cancer is the 6th most common cancer in women with estimated lifetime risk of 1 in 70 women . Epithelial ovarian cancer is the most common histological type of ovarian cancer. More than seventy percent of these patients present in the advanced stage of this disease, and have a cure rate of less than forty percent . The high mortality in these cases is due to lack of highly sensitive and specific screening methods.
Vitamin D is a fat soluble secosteroid which is involved in a wide variety of biological processes like bone metabolism, modulation of immune response, cell proliferation and cell differentiation. There exists an inverse relationship between vitamin D levels in blood and incidence of many cancers [3, 4]. The studies conducted by Arslan et al. and Tworoger et al. couldn’t establish any direct relationship between vitamin D deficiency and risk of ovarian cancer [5, 6]. But Tworoger et al. reported that vitamin D deficiency is associated with significant risk of ovarian cancer in overweight and obese women . Activity of vitamin D is mediated by vitamin D receptor (VDR). VDR gene polymorphism, FokI, (rs10735810/rs2228570) is reported to be in linkage disequilibrium with other VDR polymorphisms. A change in the sequence from C to T in the start codon translation site leads to generation of a polymorphic variant (TT) which is three amino acids longer and has decreased transactivation capacity as compared to the short CC allele . Several population based studies indicated that VDR gene polymorphisms are associated with human cancers [8, 9]. A few studies tried to establish a relationship between vitamin D receptor gene polymorphism (FokI) and ovarian cancer. The odds ratio in these studies were observed to vary from 1.09 to 2.5 indicating that CT and TT genotypes of VDR gene polymorphism (FokI) are at increased risk of ovarian cancer[10–13]. However there is hardly any data in this regard in the Indian population. Hence the present study was designed (a) to evaluate the levels of serum vitamin D in epithelial ovarian cancer patients, (b) to evaluate the association of Vitamin D receptor (VDR) gene polymorphism (FokI) with the risk of epithelial ovarian cancer and (c) to explore if the relationship between vitamin D levels and vitamin D receptor polymorphism FokI is additive in their action.
A case control study was designed to recruit fifty subjects in each group and conducted in the department of Biochemistry and department of Obstetrics and Gynecology, Maulana Azad Medical College, New Delhi. Written informed consent was taken from the cases and controls. Blood sample (5 ml) was collected from fifty newly diagnosed ovarian cancer patients who had histopathologically confirmed epithelial ovarian cancer. The study group was subjected to a structured questionnaire (regarding demographic, medical, lifestyle and reproductive information). Fifty controls were matched with respect to age, menopausal status and month of blood draw. The study was approved by the institutional ethics committee of Maulana Azad Medical College, New Delhi.
Serum vitamin D estimation
The serum vitamin D was measured by electrochemiluminescence immunoassay method using Elecsys Total Vitamin D (25-OH) kit (Roche diagnostics, Mannheim, Germany) adapted to ELECSYS 2010 (Roche diagnostics, Mannheim, Germany).
Statistical analysis was done with SPSS version 17.0 (SPSS, Inc., Chicago IL). Independent T test (for parametric data) and Mann Whitney U test (for nonparametric data) were used to compare the data. The relationship between vitamin D and ovarian cancer was determined using logistic regression. The associations between CT and TT genotypes and risk of ovarian cancer were estimated by computing the odds ratios (ORs) and their 95% confidence intervals (CIs). Synergy factor was calculated to measure the interaction between vitamin D deficiency and VDR polymorphism (FokI) . Statistical difference was considered significant for p values <0.05.
General characteristics of study population
Characteristics of epithelial ovarian cancer cases and controls
Ovarian cases (n = 50)
Controls (n = 50)
Age in yr
47.9 ± 13.35
47.2 ± 12.4
Subjects with positive family history of breast or ovarian cancer
History of use of oral contraceptives
Serum vitamin D levels
Odds ratio (OR) and 95% CI for ovarian cancer according to tertile levels of baseline vitamin D levels
Median (Range) of serum vitamin D levels in ng/ml
Ovarian cancer patients
OR (95% CI) Unadjusted
Top tertile 36 (27–47)
Bottom tertile 11.9 (5–16.2)
Median (range) of serum vitamin D (in ng/ml) in reproductive and post-menopausal age group in ovarian cancer patients and controls
Ovarian cancer patients
Reproductive age group
18.3 (7.2-61.8)(n = 19)
21.4 (7.3-40)(n = 20)
20.6 (6.93-43)(n = 30)
27.8 (7.7-47)(n = 31)
Comparison of vitamin D levels in different clinical stages and histological grading in ovarian cancer
Median (Range) of vitamin D in ng/ml
Stage I and II (n = 7)
Stage III (n = 40)
Stage IV (n = 3)
Well-differentiated (n = 6)
Moderately differentiated (n = 29)
Poorly-differentiated (n = 15)
Distribution of FF and Ff/ff genotypes in cases and healthy controls
Odds ratio (95% CI)
CT + TT (Ff + ff)
By unconditional logistic regression analysis, it was found that in comparison to the CC genotype, the CT and TT genotype (combined) were at significantly higher risk of ovarian cancer (OR = 2.37, 95% CI 1.04-5.44, p < 0.05).
Synergy factor (SF) in ovarian cancer between serum vitamin D and VDR ( Fok1) gene polymorphism
VDR gene (Fok1)
Vitamin D deficient
Ovarian cancer cases
SF (p value)
Vitamin D was known to be involved in bone metabolism but its role in other diseases like cancer, autoimmune diseases and diabetes mellitus is being studied extensively only in recent times. Ovarian cancer, on the other hand is a disease whose etiology is attributed to incessant ovulation and hormonal imbalance. Potential role of vitamin D in cancer prevention has been widely described [16–18]. There exist numerous studies which show inverse relationship of cancers of different organs with sun exposure including ovarian cancer [19–21]. However only a few studies have evaluated the role of serum vitamin D levels in ovarian cancer, and most are on Caucasian population [5, 6]. To our knowledge this is the first study showing a clear relationship between vitamin D deficiency, VDR functional polymorphism (FokI) and risk of ovarian cancer in Indian population.
It may seem surprising to see the prevalence of vitamin D deficiency in a tropical country like India. The reason behind this could be the lifestyle of people where most of the women stay indoors. The poor intake of dairy products due to social factor and dietary habits may also contribute to this. A few studies conducted on general prevalence of vitamin D deficiency in India show alarming trends [22, 23]. In our study, the participants in the highest tertile had a significant lower risk of ovarian cancer than those in the lowest tertile. On subset analysis, the mean vitamin D level of ovarian cancer (21 ± 9.1 ng/ml) was significantly lower than that of controls (26.5 ± 8.5 ng/ml) in the post-menopausal group. The reason could be that in post-menopausal state there is an increased need of vitamin D due to decreased expression of VDR caused by decrease in estrogen levels .
Summary of other studies on Fok I in ovarian cancer
Odds ratio FFvsFf/ff
Lurie et al. 2007 
Clendenen et al. 2008 
U.S + Sweden
Tworoger et al. 2009 
Lurie et al. 2010 
The increased risk of ovarian cancer in combined vitamin D deficiency and vitamin D receptor polymorphism is expected to be due to modulation of same target molecules. But we observed that low serum vitamin D levels along with homozygous TT allele didn’t lead to synergistic increase in the risk of epithelial ovarian cancer (synergy factor:2; p value < 0.4). There are other novel ligands of vitamin D receptor and co-modulators influencing vitamin D signaling mechanism [29–31]. The non-synergistic effect indicates that these novel ligands of vitamin D receptor and co-modulators might also play a role in determining the risk of ovarian cancer which is worth exploring.
It is suggested that low vitamin D levels might be a risk factor for ovarian cancer. Additionally, VDR gene (FokI) polymorphism may be a genetic modifier for ovarian cancer risk in Indian population. The homozygous FokI (TT) and heterozygous (CT) polymorphism and vitamin D levels have independent effect on cancer development and are not synergistic in their actions. However, independent large population-based prospective studies are needed to validate our findings and to facilitate rigorous analyses of subgroups. Thus our study provides evidence that the protective effect of vitamin D supplementation against ovarian cancer (especially in postmenopausal women) is worth investigating in Indian population.
We would like to thank Dr Tejinder Singh for assisting in the histopathological studies in this work.
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005,55(2):74–108. 10.3322/canjclin.55.2.74PubMedView ArticleGoogle Scholar
- National Institute for Clinical Excellence (NICE) Technology appraisal 91. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer 2005. http://guidance.nice.org.uk/TA91/Guidance/pdf/English Google Scholar
- Grant WB: Lower vitamin-D production from solar ultraviolet-B irradiance may explain some differences in cancer survival rates. J Nat Med Assoc 2006,98(3):357–364.Google Scholar
- Jenab M, Bueno-De-Mesquita HB, Ferrari P, Van Duijnhoven FJ, Norat T, Pischon T, Jansen EH, Slimani N, Byrnes G, Rinaldi S, Tjønneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Kaaks R, Linseisen J, Boeing H, Bergmann MM, Trichopoulou A, Misirli G, Trichopoulos D, Berrino F, Vineis P, Panico S, Palli D, Tumino R, Ros M, Van Gils CH: Diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case–control study. BMJ 2010, 340: B5500. 10.1136/bmj.b5500PubMed CentralPubMedView ArticleGoogle Scholar
- Arslan AA, Clendenen TV, Koenig KL, Hultdin J, Enquist K, Agren A, Lukanova A, Sjodin H, Zeleniuch-Jacquotte A, Shore R, Hallmans G, Toniolo P, Lundin E: Circulating vitamin D and risk of epithelial ovarian cancer. J Oncol 2009, 2009: 672492.PubMed CentralPubMedView ArticleGoogle Scholar
- Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE: Plasma 25-hydroxyvitamin D and 1,25-Dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007, 16: 783–788. 10.1158/1055-9965.EPI-06-0981PubMedView ArticleGoogle Scholar
- Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP: Genetics and biology of vitamin D receptor polymorphisms. Gene 2004,338(2):143–156. 10.1016/j.gene.2004.05.014PubMedView ArticleGoogle Scholar
- Raimondi S, Johansson H, Maisonneuve P, Gandini S: Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009,30(7):1170–1180. 10.1093/carcin/bgp103PubMedView ArticleGoogle Scholar
- Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J: The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009,29(9):3511–3536.PubMedGoogle Scholar
- Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT: Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2007,16(12):2566–2571. 10.1158/1055-9965.EPI-07-0753PubMedView ArticleGoogle Scholar
- Clendenen TV, Arslan AA, Koenig KL, Enquist K, Wirgin I, Agren A, Lukanova A, Sjodin H, Zeleniuch-Jacquotte A, Shore RE, Hallmans G, Toniolo P, Lundin E: Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett 2008,260(1–2):209–215.PubMed CentralPubMedView ArticleGoogle Scholar
- Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, Hankinson SE: Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res 2009,69(5):1885–1891. 10.1158/0008-5472.CAN-08-3515PubMed CentralPubMedView ArticleGoogle Scholar
- Lurie G, Wilkens LR, Thompson PJ, Carney ME, Palmieri RT, Pharoah PD, Song H, Hogdall E, Kjaer SK, Dicioccio RA, McGuire V, Whittemore AS, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Goodman MT: Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer 2010,128(4):936–943.View ArticleGoogle Scholar
- Harris SS, Eccleshall TR, Gross C, DawsonHughes B, Feldman D: The VDR start codon polymorphism (Fok-I) and bone mineral density in premenopausal American Black and White women. J Bone Miner Res 1997, 12: 1043–1048. 10.1359/jbmr.19188.8.131.523PubMedView ArticleGoogle Scholar
- Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ: The synergy factor: a statistic to measure interactions in complex diseases. BMC Res Notes 2009, 2: 105. 10.1186/1756-0500-2-105PubMed CentralPubMedView ArticleGoogle Scholar
- Webb AR, Engelsen O: Calculated ultraviolet exposure levels for a healthy vitamin D status. Photochem Photobiol 2006, 82: 1697–1703.PubMedView ArticleGoogle Scholar
- Grant WB: An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94: 1867–1875. 10.1002/cncr.10427PubMedView ArticleGoogle Scholar
- Lefkowitz ES, Garland CF: Sunlight, vitamin D, and ovarian cancer mortality rates in U.S. women. Int J Epidemiol 1994, 23: 1133–1136. 10.1093/ije/23.6.1133PubMedView ArticleGoogle Scholar
- Freedman D, Dosemeci M, McGlynn K: Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case–control study. Occup Environ Med 2002, 59: 257–262. 10.1136/oem.59.4.257PubMed CentralPubMedView ArticleGoogle Scholar
- Grant WB: Does solar ultraviolet irradiation affect cancer mortality rates in China? Asian Pacific J Cancer Prev 2007, 8: 236–242.Google Scholar
- Mohr SB, Gorham ED, Grant WB, Garland FC: Role of Ultraviolet B Irradiance and Vitamin D in Prevention of Ovarian Cancer. Am J Prev Med 2006,31(6):512–514. 10.1016/j.amepre.2006.08.018PubMedView ArticleGoogle Scholar
- Harinarayan CV, Ramalakshmi T, Prasad UV, Sudhakar D, Srinivasarao PV, Sarma KV, Kumar EG: High prevalence of low dietary calcium, high phytate consumption, and vitamin D deficiency in healthy south Indians. Am J Clin Nutr 2007, 85: 1062–1067.PubMedGoogle Scholar
- Goswami R, Kochupillai N, Gupta N, Goswami D, Singh N, Dudha A: Presence of 25(OH)D deficiency in rural north Indian village despite abundant sunshine. J Assoc Physicians India 2008, 56: 755–757.PubMedGoogle Scholar
- Duque G, El Abdaimi K, Macoritto M, Miller MM, Kremer R: Estrogens (E2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: changes with aging and hormone deprivation. Biochem Biophys Res Commun 2002,299(3):446–454. 10.1016/S0006-291X(02)02657-8PubMedView ArticleGoogle Scholar
- Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, Haussler CA, Galligan MA, Thatcher ML, Encinas Dominguez C, Haussler MR: Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 2001, 177: 145–159. 10.1016/S0303-7207(01)00406-3PubMedView ArticleGoogle Scholar
- Zmuda JM, Cauley JA, Ferrell RE: Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev 2000,22(2):203–217. 10.1093/oxfordjournals.epirev.a018033PubMedView ArticleGoogle Scholar
- Arai H, Miyamoto K, Taketani Y, Yamamoto H, Iemori Y, Morita K, Tonai T, Nishisho T, Mori S, Takeda E: A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 1997, 12: 915–921. 10.1359/jbmr.19184.108.40.2065PubMedView ArticleGoogle Scholar
- Alimirah F, Peng X, Murillo G, Mehta RG: Functional significance of vitamin D receptor FokI polymorphism in human breast cancer cells. PLoS One 2011,6(1):e16024. 10.1371/journal.pone.0016024PubMed CentralPubMedView ArticleGoogle Scholar
- Bartik L, Whitfield GK, Kaczmarska M, Lowmiller CL, Moffet EW, Furmick JK, Hernandez Z, Haussler CA, Haussler MR, Jurutka PW: Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem 2010,21(12):1153–1161. 10.1016/j.jnutbio.2009.09.012PubMed CentralPubMedView ArticleGoogle Scholar
- Egan JB, Thompson PA, Vitanov MV, Bartik L, Jacobs ET, Haussler MR, Gerner EW, Jurutka PW: Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells. Mol Carcinog 2010,49(4):337–352.PubMed CentralPubMedGoogle Scholar
- Rachez C, Suldan Z, Ward J: A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances vitamin D receptor transactivation in a cell-free system. Genes Dev 1998, 12: 1787–1800. 10.1101/gad.12.12.1787PubMed CentralPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.